Giving JW0104 together with C2402 for people with high blood pressure and high cholesterol
Official title: A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
Run by JW Pharmaceutical · NCT06643130 · Data updated 2026-11-12
This study will test whether taking JW0104 with C2402 helps people who have both hypertension and dyslipidemia control their blood pressure and cholesterol.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | JW Pharmaceutical Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | December 2, 2024 |
| Main results expected | April 2026 |
| Study ends | April 2026 |
| Registry record updated | September 9, 2025 |
| Trial ID | NCT06643130 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with both hypertension and dyslipidemia who meet the study's specified blood pressure and LDL‑C thresholds are the intended candidates.
✕Probably not a fit
People who do not meet the study's specified blood pressure or LDL‑C levels, or who have exclusionary conditions, are unlikely to be eligible or to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double‑blind, parallel Phase 3 trial planned at multiple centers to compare co‑administration of JW0104+C2402 versus JW0104+C2403 versus C2402 alone. Adults with both hypertension and dyslipidemia who meet the study's blood pressure and LDL‑C entry criteria will be enrolled and randomized to one of the three treatment arms. The trial measures efficacy outcomes related to blood pressure and lipid levels alongside safety and tolerability endpoints. Subjects who do not meet the specified msBP or LDL‑C thresholds are excluded, and dosing and visit schedules are standardized across sites.
Why it matters
Potential benefit: If successful, the combination could offer a new treatment option that improves both blood pressure and lipid control with an acceptable safety profile.
How similar studies have gone: Using combined antihypertensive and lipid‑lowering therapies is an established clinical approach, but these specific drug combinations are novel and have limited prior Phase 3 evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level
Where it's running
-
Gangdong Sacred Heart Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Minjung Kim
- Email: kmj@jwhealthcare.com
- Phone: +82-2-840-6861
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Two-drug interaction study of UIC202601 and UIC202602 in healthy adults
This study tests whether combining two investigational drugs changes how they behave in the body and whether the combination is safe in healthy volunteers.
-
Polypill Approach for Multiple Cardiovascular Risk Factors
Researchers are testing a fixed-dose pill strategy to help people aged 50–75 with high blood pressure, high cholesterol, and diabetes see if it lowers their heart-disease risk and reduces future events.
-
Goal-commitment coaching to boost proactive health actions in adults with hypertension, diabetes, or high cholesterol
This project will try a goal-commitment behavioral program to see if it helps adults with hypertension, diabetes, or high cholesterol adopt more proactive health habits.
-
Structured management of adult cardiovascular risk factors in outpatient care
This project will try a structured clinic approach to managing blood pressure, cholesterol, diabetes, and weight in adults with cardiovascular risk factors to see if it improves risk control and outcomes.
-
Digital Care for holistic health in older adults with diabetes and multiple conditions
This study tests a digital care program to help adults 50+ with type 2 diabetes and other chronic diseases improve disease control, self-management, mood, and quality of life.
-
Digital tool for doctors to prescribe exercise for people with cardiovascular risk factors
This project will test whether a new digital tool helps doctors create personalized exercise plans for adults with cardiovascular risk factors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.